ALK and lung cancer: In this study, we discovered a cell cycle dysregulation and a vulnerability of EML4‐ALK lung cancer cells to the pan‐CDK inhibitors alvocidib and dinaciclib, as well as the CDK7/12 inhibitor THZ1.